Momentum Builds: Bladder Cancer Trial Data Boost Seagen
- September 22nd, 2023
- 735 views
Astellas Pharma Inc. and Seagen Inc. (Nasdaq: SGEN) have reported promising results from the Phase 3 EV-302 clinical trial (KEYNOTE-A39) for PADCEV (enfortumab vedotin-ejfv) combined with Merck & Co., Inc.'s (NYSE: MRK) KEYTRUDA (pembrolizumab) versus traditional chemotherapy in patients with previously untreated locally advanced or metastatic urothelial cancer (la/mUC), a severe form of bladder cancer that has spread.
The study achieved its primary endpoints, showing significantly improved overall survival (OS) and progression-free survival (PFS) compared to chemotherapy. Moreover, the combination's safety profile aligns with previously reported findings for the combo enfortumab vedotin - pembrolizumab in cisplatin-ineligible la/mUC patients.
$SGEN was trading at $214.00 in pre-market, up $7.61 (+3.69%) following the announcement
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
October 29th, 2026
Treasury Sanctions Facilitators of DPRK IT Worker Fraud Targeting U.S. Businesses
October 28th, 2026Treasury Sanctions Rwandan Ministry of Defence and Financial Institution Supporting M23
October 28th, 2026October 26th, 2026FAA Releases Draft Design Standards for Vertical Flight Facilities
October 22nd, 2026
Member Login